SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors digest a string of unfavorable legal verdicts and ongoing concerns regarding AI-related capital expenditures and layoffs. Community discussions are split between those viewing the pullback as a prime dip-buying opportunity given the company's strong cash flow and those expressing deep skepticism, with many traders actively debating the impact of increasing legal scrutiny and long-term business model viability.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility as investors debate the impact of a recent short-seller report and ongoing geopolitical tensions on the stock's growth trajectory. While some community members express frustration over recent price declines and dilution concerns, bullish investors remain focused on the company's long-term potential, citing strong fundamentals, the expansion of its Galileo platform, and continued institutional support as key reasons to maintain their positions.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is facing significant downward pressure as market participants weigh broader macro volatility and sector-wide weakness against the company's high growth potential and new AI data partnerships. While some investors are actively accumulating shares based on improving fundamentals and recent insider activity, others are heavily shorting the stock, citing concerns over potential bot-driven metrics and the platform's long-term monetization sustainability.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is experiencing significant volatility as investors digest conflicting geopolitical updates from the White House regarding the Middle East, leading to intense debate over the market's direction. Community sentiment is deeply polarized, with traders closely monitoring technical support levels and reacting sharply to every headline while speculating on potential gaps and shifts in the broader economic cycle.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors react to a combination of geopolitical uncertainty and concerns that Googles new memory compression technology might dampen long-term demand for high-bandwidth chips. While some in the community see the sharp pullback as an irrational overreaction and a buying opportunity given the company's strong earnings fundamentals, others are bracing for further volatility, debating whether current price levels signal a bottom or a deeper correction for the broader semiconductor sector.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently trending as investors weigh strong CPU demand and pricing power against broader geopolitical risks and market volatility. The community remains divided, with some traders focusing on technical gap fills and tactical scalping, while others argue over the stock's long-term potential versus concerns regarding its sensitivity to global supply chain disruptions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community debate the company's financial viability and the impact of the ongoing conflict in the Middle East on market stability. Discussion is dominated by heated political discourse, skepticism regarding the firm's revenue models, and concerns over potential stock volatility linked to evolving geopolitical news.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending due to a significant private placement and investor excitement surrounding its INHBE-targeting obesity drug, WVE-007, which is being touted for its potential to drive 'quality' weight loss through visceral fat reduction and muscle preservation. While some community members are bullish on the company's platform and long-term outlook, others are expressing caution regarding recent insider selling and the volatility typical of early-stage biotech trials.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently experiencing extreme volatility and intense community frustration following a reverse stock split, with investors aggressively debating whether the move is a setup for a potential short squeeze or a terminal decline. The conversation is dominated by allegations of management silence and mismanagement, while retail traders remain sharply divided between those calling for a mass exit and those holding out for a miraculous turnaround fueled by institutional interest.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending as traders debate its strategic pivot into healthcare following the Carve acquisition, with community members closely watching whether its newfound focus on scarce TCM assets and biotech can successfully complement its existing energy and smart-tech footprint. While skeptics highlight the company's history of dilution and reliance on speculative M&A, momentum traders are eyeing the tight float and the potential for a technical breakout as the stock maintains a base above key support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities researchers at Zacks Research issued their Q1 2026 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

FY2028 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Research issued their FY2028 earnings estimates for Tonix Pharmaceuticals in a note issued to...

Seth Lederman Purchases 15,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, for a total transaction of $223,350.00. Following...

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following...

Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Noble Financial upped their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a research note issued on...

<ul class="summary-bullets"><li>CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization.</li><li>Investors are also watching TNX-4800, with the company planning FDA talks on Phase 2/3 development and potential studies beginning in 2027-2028.</li><li>Tonix posted a net loss of $46.9 million in Q4, compared with a net loss of $22.1 million a year ago.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) rose over 1% in premarket trading on Friday as investors cheered early prescription traction for its fibromyalgia drug Tonmya and growing interest in its Lyme disease prevention program, despite a wider quarterly loss.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is headed for its seventh straight week of losses and has declined 0.3% so far this week.<h2 class="st-heading-2">Tonmya Launch Gains Early Prescriber Traction</h2>Tonix said Tonmya, approved by the U.S. Food and Drug Administration (FDA) in August 2025 for fibromyalgia in adults, is showing early adoption after its Nov.17, 2025, commercial launch. The therapy is the first new prescription medicine approved for fibromyalgia in more than 15 years.Through Feb.27, more than 1,500 healthcare providers had prescribed Tonmya, about 2,500 patients had initiated treatment and cumulative prescriptions reached nearly 4,200, including bridge prescriptions provided through the company’s specialty pharmacy channel.“Early prescription trends reflect favorable prescriber uptake and repeat utilization consistent with our internal launch expectations,” CEO Seth Lederman said in a statement. Tonix has established distribution through wholesalers, specialty pharmacies, and patient support programs, including copay assistance and prior authorization services.Speaking at the Life Sciences Virtual Investor Forum on Wednesday, Lederman said early anecdotal feedback suggests patients are reporting positive results and that prescribing is occurring across multiple specialties, including rheumatology, primary care, pain management and neurology.<h2 class="st-heading-2">Lyme Disease Prevention Drug In Focus</h2>Investors have also been paying attention to TNX-4800, a long-acting monoclonal antibody for the seasonal prevention of Lyme disease, an area with no FDA-approved vaccines or prophylactic treatments currently available.Tonix plans to meet with the FDA this year to discuss Phase 2/3 development options, including a field study and a controlled human infection model study. The company expects investigational products to be available in early 2027, with a U.S. field study potentially beginning in 2027 and a human challenge study planned for 2028.<h2 class="st-heading-2">TNXP Q4 Review</h2>Tonix reported fourth-quarter (Q4) revenue of about $534 million, significantly up from $2.6 million a year earlier. However, the company posted a net loss of $46.9 million, or $3.98 per share, compared with a net loss of $22.1 million, or $9.77 per share, in the same period a year ago.Tonix ended 2025 with $207.6 million in cash and cash equivalents, which will fund operations into the first quarter of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TNXP was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tnxp_ss_png_63ee8c6e92.webp" alt="tnxp ss.png" width="969" height="141"><figcaption>TNXP sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/curiousturtle2000/message/647416946">called</a> Tonix’s latest&nbsp;earnings report “very encouraging.”<stembedurl>https://stocktwits.com/curiousturtle2000/message/647416946</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/StockJayC/message/647411678">said</a>, “$20m-$25m cash burn = 2 years continuing at the current burn with no change to operations or factoring revenue increases,” adding that they expect the stock to rise over $60 by June.&nbsp;<stembedurl>https://stocktwits.com/StockJayC/message/647411678</stembedurl>TNXP stock has declined 14% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print

Tonmya launch gained early uptake, with over 1,500 healthcare providers prescribing the drug until Feb.27.

Equity

Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its earnings results on Thursday. The company reported ($4.15) EPS for the quarter, missing the consensus estimate of ($3.16) by...

Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

ManoJaggarwal bullish call on $MU at $68.07

FinnessaurusFlex bullish call on $ASTS at $1.98

NeverFadeTheOracle bullish call on $SNDK at $41.95

stockwinner1966 bullish call on $USAS at $0.42

Celebrating the single best "called shot" of the year. This award honors a trade that combined timing with conviction, proving that market mastery is an art.

Stocktwits

Stocktwits Polls

Retail investors are closely tracking new insurance approvals and formulary additions for the flagship product as a signal for mass-market adoption.

Bullish traders are highlighting high short interest and limited float as the primary catalyst for a potential explosive price reversal.

Traders are optimistic about future phase-1 data for Lyme disease and migraine treatments driving long-term value despite recent volatility.

Skeptics continue to highlight history of share dilution and reverse splits as a barrier to sustained stock price growth.

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp